Journal article
Integrated supervised consumption services and hepatitis C testing and treatment among people who inject drugs in Toronto, Canada: A cross‐sectional analysis
Journal of viral hepatitis, v 30(2), pp 160-171
Feb 2023
PMID: 36461705
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Despite the availability of publicly funded hepatitis C (HCV) treatment in Canada, treatment gaps persist, particularly among people who inject drugs. We estimate correlates of HCV care cascade engagement (testing, diagnosis, and treatment) among people who inject drugs in Toronto, Canada and examine the effect of accessing differing supervised consumption service (SCS) models on self‐reported HCV testing and treatment. This is a cross‐sectional baseline analysis of 701 people who inject drugs surveyed in the Toronto, Ontario integrated Supervised Injection Services (OiSIS‐Toronto) study between November 2018 and March 2020. We examine correlates of self‐reported HCV care cascade outcomes including SCS model, demographic, socio‐structural, drug use, and harm reduction characteristics. Overall, 647 participants (92%) reported ever receiving HCV testing, of whom 336 (52%) had been diagnosed with HCV. Among participants who reported ever being diagnosed with HCV, 281 (84%) reported chronic HCV, of whom 130 (46%) reported HCV treatment uptake and 151 (54%) remained untreated. Compared to those with no SCS use, participants who had ever injected at an integrated SCS model with co‐located HCV care had greater prevalence of both ever receiving HCV testing (adjusted prevalence ratio [aPR]: 1.12, 95% confidence interval [CI]: 1.02–1.24) and ever receiving HCV treatment (aPR: 1.67, 95% CI: 1.04–2.69). Over half of participants diagnosed with chronic HCV reported remaining untreated. Our findings suggest that integrated SCS models with co‐located HCV care represent key strategies for linkage to HCV care, but that more is needed to support scale‐up.
Metrics
Details
- Title
- Integrated supervised consumption services and hepatitis C testing and treatment among people who inject drugs in Toronto, Canada: A cross‐sectional analysis
- Creators
- Zoë R. Greenwald - University of TorontoZachary Bouck - University of TorontoElizabeth McLean - Centre on Drug Policy Evaluation, MAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, ON, Canada.Kate Mason - Regent Park Community Health CentreBernadette Lettner - Regent Park Community Health CentreJennifer Broad - Regent Park Community Health CentreZoë Dodd - St. Michael's HospitalTanner Nassau - Drexel UniversityAyden I. Scheim - Drexel UniversityDan Werb - University of Toronto
- Publication Details
- Journal of viral hepatitis, v 30(2), pp 160-171
- Publisher
- Wiley
- Number of pages
- 12
- Grant note
- Canadian Institutes of Health Research (NPC‐178912; PJT‐153152) CIHR New Investigator Salary Award St. Michael's Hospital Foundation CIHR Doctoral Award: Frederick Banting and Charles Best Canadian Graduate Scholarship (202011FBD‐457278‐253354) Public Health Agency of Canada Ontario Ministry of Research Innovation and Science Early Research Award Canadian Network on Hepatitis C (CanHepC)
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Dana and David Dornsife School of Public Health; Epidemiology and Biostatistics
- Web of Science ID
- WOS:000900035200001
- Scopus ID
- 2-s2.0-85144294676
- Other Identifier
- 991020099922704721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Gastroenterology & Hepatology
- Infectious Diseases
- Virology